Lv3
320 积分 2026-02-09 加入
Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials
28天前
已完结
Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists
1个月前
已完结
Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists
1个月前
已完结
Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis
1个月前
已完结
Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis
1个月前
已完结
Impact of GLP-1 receptor agonist-induced weight loss on 22 cancers in the next ten years using a Markov state-transition model – A UK weight and wellness cancer landscape analysis
1个月前
已关闭
Overscreening of patients on glucagon-like peptide-1 receptor agonists: A second “epidemic” of thyroid cancer overdiagnosis?
1个月前
已关闭
Evaluating Thyroid Cancer Risk in Glucagon-like Peptide-1 Analog Users With Thyroid Nodules
1个月前
已完结
Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study
1个月前
已完结
Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials
1个月前
已完结
皖公网安备34019202002308
